We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cancer Cells 3D Printed to Mimic Tumors

By LabMedica International staff writers
Posted on 24 Apr 2014
A group of Chinese and American researchers have successfully created a three-dimensional (3D) model of a cancerous tumor using a 3D printer.

The model, which consists of a scaffold of fibrous proteins coated in cervical cancer cells, has provided an accurate 3D representation of a tumor’s environment and could help in the discovery of new drugs and cast new light on how tumors develop, grow, and metastasize throughout the body.

The study’s findings were published April 11, 2014, in the Institute of Physics (IOP) Publishing’s journal Biofabrication. The model consists of a grid structure, 10 mm in width and length, composed of gelatin, alginate, and fibrin, which recreates the fibrous proteins that make up the extracellular matrix of a tumor.

The grid structure is coated in Hela cells—an unusual, “immortal” cell line that was first derived from a cervical cancer patient in 1951. More...
Because the cells’ ability to divide forever in a laboratory setting, the cell line has been used in some of the most substantial scientific studies of the past 50 years.

Although the most effective approach to studying tumors is to do so in a clinical trial, ethical and safety restrictions make it hard for these types of studies to be performed on a wide scale. To overcome this, 2D models, consisting of a single layer of cells, have been created to mimic the physiologic environment of tumors so that different types of drugs can be evaluated in a realistic manner. With the dawn of 3D printing, it is now possible to provide a more realistic representation of the environment surrounding a tumor, which the researchers have demonstrated in this study by comparing results from their 3D model with results from a 2D model.

In addition to assessing if the cells remained viable (alive) after printing, the researchers also examined how the cells proliferated, how they expressed a specific set of proteins, and how resistant they were to anticancer agents. The proteins examined were part of the matrix metalloproteinases (MMP) protein family. These proteins are used by cancer cells to break through their surrounding matrix and help tumors to spread. Resistance to anticancer drugs, which was also studied, is a good indicator of tumor malignancy.

The findings revealed that 90% of the cancer cells remained viable after the printing process. The findings also demonstrated that the 3D model had more similar characteristics to a tumor compared to 2D models and in the 3D model the cancer cells showed a higher proliferation rate, higher protein expression and higher resistance to anticancer drugs.

The lead author of the research, Prof. Wei Sun, from Tsinghua University (Beijing, China), and Drexel University (Philadelphia, PA, USA), said, “We have provided a scalable and versatile 3D cancer model that shows a greater resemblance to natural cancer than 2D cultured cancer cells. With further understanding of these 3D models, we can use them to study the development, invasion, metastasis and treatment of cancer using specific cancer cells from patients. We can also use these models to test the efficacy and safety of new cancer treatment therapies and new cancer drugs.”

Related Links:

Tsinghua University
Drexel University



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.